Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk

Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression

(2022) Joseph Kamtchum-Tatuene et al.   CIRCULATION RESEARCH

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

(2021) Paul M Ridker et al.   CIRCULATION RESEARCH

Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R

(2021) Arjen J. Cupido et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Targeting Interleukin-1 and Interleukin-6

(2020) Paul M Ridker   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Colchicine in Patients with Chronic Coronary Disease

(2020) Stefan M. Nidorf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence for a protective role of placental growth factor in cardiovascular disease

(2020) Yihong Chen et al.   Science Translational Medicine

High Levels of Soluble Lectinlike Oxidized Low‐Density Lipoprotein Receptor‐1 Are Associated With Carotid Plaque Inflammation and Increased Risk of Ischemic Stroke

(2019) Hanna Markstad et al.   Journal of the American Heart Association

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

(2019) Jean-Claude Tardif et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   CARDIOVASCULAR RESEARCH

OUP accepted manuscript

(2018)   EUROPEAN HEART JOURNAL

The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling

(2018) Paul Baran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130

(2017) Mario Luca Morieri et al.   MEDIATORS OF INFLAMMATION

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Markers of Death Receptor-Activated Apoptosis are Associated with Increased Risk for Development of Diabetes and Cardiovascular Disease

(2017) Ingrid Yao Mattisson et al.   EBioMedicine

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

(2016) Sylvia Heink et al.   NATURE IMMUNOLOGY

Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction

(2015) Ilais Moreno Velásquez et al.   ATHEROSCLEROSIS

Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study

(2015) A. C. Shore et al.   JOURNAL OF INTERNAL MEDICINE

Impaired Fibrous Repair

(2014) Andreas Edsfeldt et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

(2012)   LANCET

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice

(2011) Harald Schuett et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor

(2010) M. M. McFarland-Mancini et al.   JOURNAL OF IMMUNOLOGY